Trial Profile
Reducing medical risks in individuals with bipolar disorder: enhancing outcomes with aripiprazole.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 24 Nov 2017
Price :
$35
*
At a glance
- Drugs Aripiprazole (Primary)
- Indications Bipolar disorders
- Focus Pharmacodynamics
- 23 Dec 2009 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
- 23 Dec 2009 Planned end date changed from 1 Mar 2010 to 1 Aug 2009 as reported by ClinicalTrials.gov.
- 13 May 2008 New trial record.